UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

The 2016 revision of WHO classification of myeloproliferative neoplasms: Clinical and molecular advances

Blood reviews, 2016-11, Vol.30 (6), p.453-459

2016

Volltextzugriff (PDF)

Somatic CALR Mutations in Myeloproliferative Neoplasms with Nonmutated JAK2

The New England journal of medicine, 2013-12, Vol.369 (25), p.2391-2405

2013

Volltextzugriff (PDF)

Philadelphia chromosome-negative chronic myeloproliferative neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Annals of oncology, 2015-09, Vol.26, p.v85-v99

2015

Volltextzugriff (PDF)

P17 CLONAL PLASMA‐CELLS IN STEM CELL APHERESIS AS A PREDICTOR OF PROGRESSION IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS ELEGIBLE FOR AUTOLOGOUS STEM CELL TRANSPLANTATION

HemaSphere, 2023-05, Vol.7 (S2), p.19-19

2023

Volltextzugriff (PDF)

Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis

Leukemia, 2016-08, Vol.30 (8), p.1701-1707

2016

Volltextzugriff (PDF)

An overview on CALR and CSF3R mutations and a proposal for revision of WHO diagnostic criteria for myeloproliferative neoplasms

Leukemia, 2014-07, Vol.28 (7), p.1407-1413

2014

Volltextzugriff (PDF)

CALR and ASXL1 mutations-based molecular prognostication in primary myelofibrosis: an international study of 570 patients

Leukemia, 2014-07, Vol.28 (7), p.1494-1500

2014

Volltextzugriff (PDF)

Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study

Leukemia, 2013-09, Vol.27 (9), p.1874-1881

2013

Volltextzugriff (PDF)

Indication and management of allogeneic stem cell transplantation in primary myelofibrosis: a consensus process by an EBMT/ELN international working group

Leukemia, 2015-11, Vol.29 (11), p.2126-2133

2015

Volltextzugriff (PDF)

The number of prognostically detrimental mutations and prognosis in primary myelofibrosis: an international study of 797 patients

Leukemia, 2014-09, Vol.28 (9), p.1804-1810

2014

Volltextzugriff (PDF)

Mutations and prognosis in primary myelofibrosis

Leukemia, 2013-09, Vol.27 (9), p.1861-1869

2013

Volltextzugriff (PDF)

Problems and pitfalls regarding WHO-defined diagnosis of early/prefibrotic primary myelofibrosis versus essential thrombocythemia

Leukemia, 2013-10, Vol.27 (10), p.1953-1958

2013

Volltextzugriff (PDF)

IDH1 and IDH2 mutation studies in 1473 patients with chronic-, fibrotic- or blast-phase essential thrombocythemia, polycythemia vera or myelofibrosis

Leukemia, 2010-07, Vol.24 (7), p.1302-1309

2010

Volltextzugriff (PDF)

Incidence and risk factors for bleeding in 1104 patients with essential thrombocythemia or prefibrotic myelofibrosis diagnosed according to the 2008 WHO criteria

Leukemia, 2012-04, Vol.26 (4), p.716-719

2012

Volltextzugriff (PDF)

JAK inhibitor therapy for myelofibrosis: critical assessment of value and limitations

Leukemia, 2011-02, Vol.25 (2), p.218-225

2011

Volltextzugriff (PDF)

Rethinking the diagnostic criteria of polycythemia vera

Leukemia, 2014-06, Vol.28 (6), p.1191-1195

2014

Volltextzugriff (PDF)

Kaposi sarcoma in a patient treated with ruxolitinib

Annals of oncology, 2017-07, Vol.28 (7), p.1670-1671

2017

Volltextzugriff (PDF)

Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the international working group for myelofibrosis research and treatment

Leukemia, 2008-02, Vol.22 (2), p.437-438

2008

Volltextzugriff (PDF)

Calreticulin mutation-specific immunostaining in myeloproliferative neoplasms: pathogenetic insight and diagnostic value

Leukemia, 2014-09, Vol.28 (9), p.1811-1818

2014

Volltextzugriff (PDF)

Elevated C-reactive protein is associated with shortened leukemia-free survival in patients with myelofibrosis

Leukemia, 2013-10, Vol.27 (10), p.2084-2086

2013

Volltextzugriff (PDF)

Humoral and cellular responses after third dose of SARS-CoV-2 vaccine in myeloproliferative neoplasms patients on ruxolitinib therapy

Leukemia research, 2023-08, Vol.131, p.107330-107330, Article 107330

2023

Volltextzugriff (PDF)

Primary myelofibrosis with or without mutant MPL: comparison of survival and clinical features involving 603 patients

Leukemia, 2011-12, Vol.25 (12), p.1834-1839

2011

Volltextzugriff (PDF)

The rate of transformation from JAK2-mutated ET to PV is influenced by an accurate WHO-defined clinico-morphological diagnosis

Leukemia, 2015-04, Vol.29 (4), p.992-993

2015

Volltextzugriff (PDF)

CALR mutation, MPL mutation and triple negativity identify patients with the lowest vascular risk in primary myelofibrosis

Leukemia, 2015-05, Vol.29 (5), p.1209-1210

2015

Volltextzugriff (PDF)

1 – 25 von 67

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(66)
Mit Volltextzugriff
(58)

Publikationsform

Artikel
(67)

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

9 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

The 2016 revision of WHO classification of myeloproliferative neoplasms: Clinical and molecular advances

Somatic CALR Mutations in Myeloproliferative Neoplasms with Nonmutated JAK2

Philadelphia chromosome-negative chronic myeloproliferative neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

P17 CLONAL PLASMA‐CELLS IN STEM CELL APHERESIS AS A PREDICTOR OF PROGRESSION IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS ELEGIBLE FOR AUTOLOGOUS STEM CELL TRANSPLANTATION

Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis

An overview on CALR and CSF3R mutations and a proposal for revision of WHO diagnostic criteria for myeloproliferative neoplasms

CALR and ASXL1 mutations-based molecular prognostication in primary myelofibrosis: an international study of 570 patients

Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study

Indication and management of allogeneic stem cell transplantation in primary myelofibrosis: a consensus process by an EBMT/ELN international working group

The number of prognostically detrimental mutations and prognosis in primary myelofibrosis: an international study of 797 patients

Mutations and prognosis in primary myelofibrosis

Problems and pitfalls regarding WHO-defined diagnosis of early/prefibrotic primary myelofibrosis versus essential thrombocythemia

IDH1 and IDH2 mutation studies in 1473 patients with chronic-, fibrotic- or blast-phase essential thrombocythemia, polycythemia vera or myelofibrosis

Incidence and risk factors for bleeding in 1104 patients with essential thrombocythemia or prefibrotic myelofibrosis diagnosed according to the 2008 WHO criteria

JAK inhibitor therapy for myelofibrosis: critical assessment of value and limitations

Rethinking the diagnostic criteria of polycythemia vera

Kaposi sarcoma in a patient treated with ruxolitinib

Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the international working group for myelofibrosis research and treatment

Calreticulin mutation-specific immunostaining in myeloproliferative neoplasms: pathogenetic insight and diagnostic value

Elevated C-reactive protein is associated with shortened leukemia-free survival in patients with myelofibrosis

Humoral and cellular responses after third dose of SARS-CoV-2 vaccine in myeloproliferative neoplasms patients on ruxolitinib therapy

Primary myelofibrosis with or without mutant MPL: comparison of survival and clinical features involving 603 patients

Clinical end points for drug treatment trials in BCR-ABL1-negative classic myeloproliferative neoplasms: consensus statements from European LeukemiaNET (ELN) and Internation Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT)

The rate of transformation from JAK2-mutated ET to PV is influenced by an accurate WHO-defined clinico-morphological diagnosis

CALR mutation, MPL mutation and triple negativity identify patients with the lowest vascular risk in primary myelofibrosis

Suchergebnisse filtern